Consistency, high quality, and standardization to make medical cannabis accessible for those who need it
Panaxia is modernizing the medical field with revolutionary pharmaceutical solutions that utilize the benefits of cannabis. We spearhead innovation in pharmaceutical cannabis by constantly introducing cannabis-based products that radically improve the lives of people suffering from a wide range of medical conditions. Panaxia differs from other companies because our consistent and precise products are formulated in delivery methods that make sense for more patients.
Decades of experience to lead the way forward
Panaxia is part of a leading group of Israeli pharmaceutical companies with over four decades of experience in the pharmaceutical industry. We are innovators—and our relentless emphasis on research and development means that today our entire group of companies offers more than 600 medical products in over 30 international markets to treat a wide range of symptoms and conditions.
Research. Develop. Repeat.
As pharmaceutical research on cannabis continues to evolve, we intend to stay at the forefront of the field. With over 20 percent of our workforce dedicated to research and development, we are committed to continuously increasing our knowledge and understanding of this plant’s wide range of therapeutic benefits. Our goal is to increase accessibility to pharmaceutical cannabis with cutting-edge products and a variety of new and familiar delivery methods.
Quality and accuracy that caregivers and patients can depend on
Cannabis is a potent therapeutic, but its efficacy has been crippled by imprecise dosing, lack of standardization, inconsistency, and cumbersome delivery. Panaxia is committed to changing all that by bringing to the market products that follow the strictest pharma standards including highly advanced and validated analytical methods. We develop dosage forms that deliver a consistent amount of active ingredients to patients—time after time.
Led by Experience.
Dr. Dadi Segal, Ph.D
CEO & Founder
Ph.D: Computational Chemistry
Sigal Ben Eli
Dr. Eran Goldberg, Ph.D
Ph.D: Plant Sciences
Board of Directors
Viola Growth, General Partner
Goldman Sachs, Partner & Head of Israel
Prof. Aaron Ciechanover
Nobel Prize Laureate in Chemistry and Distinguished Research Israel Institute of Technology, Professor
Prof. David (Dedi) Meiri
Cancer Biology and Cannabinoid Research
Biology and Cannabinoid Research Laboratory of Cancer
Prof. Markus Veit, Ph.D
Herbal medicinal products and
plant phenolics. Founder, Alphatopics, GmbH
Dr. Noa Leibobvitch
Ph.D: Physiology & Pharmacology. Teva, Global Head of Branded Product Development
Scientific Team Leaders
Analytical R&D manager
Dr. Sheina Tarlovski
MD: Doctor of Medicine